The CEO of Cardax Inc. said the selection of the company's astaxanthin compound CDX-085 to take part in the National Institute on Aging's anti-aging interventions testing program will have positive implications for the Hawaii-based business.
The program, among the top aging research programs in the U.S., is funded by the National Institutes of Health and only selects 4-5 compounds every year through extensive screening for their potential impact on lifespan extension and their ability to delay disease…
The CEO of Cardax Inc. said the selection of the company's astaxanthin compound CDX-085 to take part in the National Institute on Aging's anti-aging interventions testing program will have positive implications for the Hawaii-based business.
The program, among the top aging research programs in the U.S., is funded by the National Institutes of Health and only selects 4-5 compounds every year through extensive screening for their potential impact on lifespan extension and their ability to delay disease…